Molecular Therapy: Oncolytics (Sep 2022)

Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation

  • Xuecen Wang,
  • Zhirui Cao,
  • Xin Yue,
  • Tingyu Liu,
  • Gesi Wen,
  • Dongmei Jiang,
  • Weijian Wu,
  • Liyuan Le,
  • Yan Wang,
  • Chengtao Wang,
  • Ziyang Wang,
  • Meng Jin,
  • Meiyan Zhu,
  • Shasha He,
  • Xiaoyue Zhang,
  • Xianzhang Bu,
  • Ran-yi Liu,
  • Zhenwei Peng,
  • Yong Chen

Journal volume & issue
Vol. 26
pp. 330 – 346

Abstract

Read online

The use of radiotherapy for hypopharyngeal cancer (HC) treatment is increasing, and it is currently the primary treatment option for this cancer. However, radioresistance occurs in a proportion of patients. Here, we found that radiation increased proteasomal gene expression and that proteasome assembly was dependent on the induction of transcription factor NRF1 in HC. Through screening assays, we identified a mechanism by which proteasome-mediated degradation of DEP domain-containing mTOR-interacting protein (DEPTOR) contributes to the elevation of mTORC1 signaling after radiation. Therefore, after treatment with proteasome inhibitors (PIs), stabilization of DEPTOR inhibited mTORC1 signaling elevated by radiation and ultimately sensitized HC to radiotherapy. Mechanically, PIs not only interrupted the deubiquitination and degradation of DEPTOR but also suppressed the ubiquitination of DEPTOR mediated by β-TrCP. Clinically, the high levels of DEPTOR in HC cells were associated with sensitivity to radiotherapy and favorable prognosis. Stabilizing DEPTOR through targeting proteasome-mediated degradation is a potential strategy for sensitizing HC to radiotherapy.

Keywords